Foreword - Will HPV vaccines prevent cervical cancers among poor women of color?: Global health policy at the intersection of human rights and intellectual property law

American Journal of Law and Medicine

Volumn 35, Issue 2-3, 2009, Pages 247-252

  Outterson, Kevin ^a,b  

^a Department of Law ^*  (United Kingdom)

^b BOSTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

EDITORIAL; FEMALE; HEALTH CARE POLICY; HUMAN; HUMAN RIGHTS; NEGRO; PATENT; POVERTY; UTERINE CERVIX TUMOR; VIROLOGY; WOMEN'S HEALTH;

AFRICAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEALTH POLICY; HUMAN RIGHTS; HUMANS; INTELLECTUAL PROPERTY; PAPILLOMAVIRUS VACCINES; POVERTY; UTERINE CERVICAL NEOPLASMS; WOMEN'S HEALTH;

EID: 70249122757     PISSN: 00988588     EISSN: None     Source Type: Journal    
DOI: 10.1177/009885880903500201     Document Type: Review

References (32)

1. Joanna N. Erdman, Human Rights in Health Equity: Cervical Cancer and HPV Vaccines, 35 AM. J. L. & MED. 365, 366 (2009).
2. See Emmanuela Gakidou et al., Coverage of Cervical Cancer Screening in 57 Countries: Low Average Levels and Large Inequalities, 5 PLOS MEDICINE 863, 863 (2008);
3. R. Sankaranarayanan et al., Effective Screening Programmes for Cervical Cancer in Low-and Middle-Income Developing Countries, 79 BULLETIN OF THE WORLD HEALTH ORGANIZATION 954-62 (2001).
4. S. M. Garland et al., Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases, 356 NEW ENG. J. MED. 1928-43 (2007).
5. J. Tanne, CDC Recommends Expensive Vaccine for All Girls Aged 11-12, 333 BRITISH MED. J. 114 (2006).
6. Kevin Outterson & Aaron S. Kesselheim, Market-Based Licensing For HPV Vaccines in Developing Countries, 27 HEALTH AFFAIRS 130, 135 (2008);
7. Erdman, supra note 1, at 387
8. F. Kamangar et al., Patterns of Cancer Incidence, Mortality, and Prevalence Across Five Continents: Defining Priorities to Reduce Cancer Disparities in Different Geographic Regions of the World, 24 J. CLINICAL ONCOLOGY 2137-50 (2006).
9. Outterson & Kesselheim, supra note 5, at 134-35.
10. RA. Charo, Politics, Parents, and Prophylaxis-Mandating HPV Vaccination in the United States, 356 NEW ENG. J. MED. 1905-08 (2007).
11. Sara E. Crager et al., University Contributions to the HPV Vaccine and Implications for Access to Vaccines in Developing Countries: Addressing Materials and Know-how in University Technology Transfer Policy, 35 AM. J. L. T MED. 253 (2009).
12. Beirne Roose-Snyder & Megan K. Doyle, Global Health Licensing Program: A New Model For Humanitarian Licensing at the University Level, 35 AM. J. L. AT MED. 281 (2009).
13. April E. Effort & Ashley J. Stevens, Using Academic License Agreements to Promote Global Social Responsibility, 43 LES NOUVELLES: J. LICENSING EXECUTIVES SOC'R 85 (2008). Ashley Stevens discussed this paper at the Symposium.
14. a Jon Kim Andrus et al., New Vaccines for Developing Countries: Will it be Feast of Famine?, 35 AM. J. L. & MED. 311 (2009).
15. Mexico is not a Revolving Fund recipient country.
16. The cost effective price in Brazil has been estimated at approximately $25.
17. Jan M. Agosti & Sue J. Goldie, Introducing HPV Vaccine in Developing Countries - Key Challenges and Issues, 356 NEW ENG. J. MED. 1908, 1909-10 (2007). In poorer countries with per capital incomes around $1000, the cost effective price is in the range of $3 to $6.
18. HELEN SAXENIAN, PROGRAM FOR APPROPRIATE TECHNOLOGY HEALTH (PATH), HPV VACCINE ADOPTION IN DEVELOPING COUNTRIES: COST AND FINANCING ISSUES 8-11 (2007).
19. See Kevin Outterson, Pharmaceutical Arbitrage: Balancing Access and Innovation in International Prescription Drug Markets, 5 YALE J. HEALTH POL'Y L. & ETHICS 193, 203-05 (2005).
20. Peter Maybarduk & Sarah Rimmington, Compulsory Licenses: A Tool to Improve Global Access to the HPV Vaccine?, 35 AM. J. L. & MED. 323 (2009).
21. Abigail English et al., Clinical Preventive Services for Adolescents: Position Paper of the Societyfor Adolescent Medicine, 35 AM. J. L. & MED. 351 (2009).
22. U. N. Convention on the Rights of the Child, G. A. Res. 44/25, U. N. Doc. A/RES/44/25 (Nov. 20, 1989), at Art. 24. The United States is not a party to this Convention.
23. English, supra note 17.
24. Erdman, supra note 1.
25. Erdman, supra note 1, at 380.
26. Id. at 381.
27. Gregory D. Zimet, Potential Barriers to HPV Immunization: From Public Health to Personal Choice, 35 AM. J. L. & MED. 389, 393-98 (2009).
28. Vivien Davis Tsu, Overcoming Barriers And Ensuring Access to HPV Vaccines in Low-Income Countries, 35 AM. J. L. & MED. 401, 409 (2009).
29. Id. at 404-05.
30. Id. at 408.
31. Outterson & Kesselheim, supra note 5, at 135.
32. Sean McElligott, Addressing Supply Side Barriers To Introduction of New Vaccines To the Developing World, 35 AM. J. L. & MED. 415 (2009).